Pantherna Therapeutics collaborates with Charité – Universitätsmedizin Berlin to investigate the potential of therapeutic mRNA in autoimmune disease

Research collaboration of Pantherna Therapeutics with Charité clinician scientists will explore the use of lipid-nanoparticle formulated mRNA for therapeutic vaccination

Pantherna, a privately-held German biotech company, developing new mRNA therapies, today announced a research collaboration with Charité – Universitätsmedizin Berlin, exploring the potential of mRNA therapies in treating autoimmune diseases. Together with clinician scientists from the Charité Department of Clinical Neuroimmunology Pantherna aims to investigate the potential of its PTX-mRNA and PTX-LNP technologies as a therapeutic means to fight autoimmune diseases.  Neurological conditions such as Neuromyelitis optica spectrum disorders (NMOSD) are caused by auto-antibodies attacking endogenous proteins and consequently destroying essential cells such as astrocytes or oligodendrocytes. Despite immunosuppressive amelioration of the symptoms no specific treatment exists for this rare debilitating chronic disease. Prof. Friedemann Paul and Dr. Maria Hastermann and their team at Charité unravel the pathological basis for autoimmunity in NMOSD and strive to find novel therapeutic modalities. Both parties agreed on the conduct of preclinical studies, addressing the suitability of novel LNP-compositions to control tolerogenic immune responses.

Contact for additional information:

Pantherna Therapeutics GmbH

Dr. Ansgar Santel, Head of Translational Research and Alliance Management
T: +49(0)3302-202 240-0